Despite the improved care of systemic lupus erythematosus (SLE), a cure for this chronic and disabling disease is still not available. Refractory disease manifestations and treatment-related complications are still major causes of mortality and morbidity.
To further improve the prognosis of SLE, more efficacious therapies with fewer adverse effects are necessary. These can be achieved by modification of conventional treatment regimens, combination strategies and targeted therapies. Owing to the clinical and immunological heterogeneity of SLE, studies on serum and cellular biomarkers are needed to identify subsets of patients who will benefit from newer therapies.
Sumber : Medical Progress e newspaper
Read More »